Company profile for Icosavax

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. We were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. By utilizing computationally designed prot...
We are committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. We were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2815 Eastlake Ave E, Suite 300 Seattle, WA 98102
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
AstraZeneca completes acquisition of Icosavax
AstraZeneca completes acquisition of Icosavax

21 Feb 2024

// INDIAN PHARMA POST

https://www.indianpharmapost.com/news/astrazeneca-completes-acquisition-of-icosavax-15295

INDIAN PHARMA POST
21 Feb 2024

https://www.biospace.com/article/astrazeneca-buys-into-rsv-vaccine-market-with-potential-1-1b-icosavax-purchase/

BIOSPACE
13 Dec 2023

https://investors.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-2-results

PRESS RELEASE
12 Dec 2023

https://www.globenewswire.com//news-release/2023/11/14/2780510/0/en/Icosavax-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
14 Nov 2023

https://www.globenewswire.com//news-release/2023/11/08/2776171/0/en/Icosavax-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html

GLOBENEWSWIRE
08 Nov 2023

https://www.globenewswire.com//news-release/2023/10/31/2770090/0/en/Icosavax-to-Participate-in-the-Guggenheim-Healthcare-Talks-5th-Annual-Inflammation-Neurology-Immunology-INI-Conference.html

GLOBENEWSWIRE
31 Oct 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty